Lafitte Marie, Sirvent Audrey, Roche Serge
CRBM, CNRS, Univ. Montpellier, Montpellier, France.
Front Oncol. 2020 Feb 12;10:125. doi: 10.3389/fonc.2020.00125. eCollection 2020.
Colorectal cancer (CRC) is one of the leading causes of tumor-related death worldwide. While surgery can cure patients with early stage CRC, the 5-year survival rate is only 10% for patients with metastatic disease. Therefore, new anti-metastatic therapies are needed for this cancer. Metastatic spread defines the dissemination of cancer cells with tumor-initiating capacities from the primary tumor and their colonization of distinct organs, mainly the liver, for secondary tumor formation. Although the underlying mechanisms are not fully understood, components of the tumor microenvironment have gained strong interest. Among the known metastatic-promoting factors, collagens are extracellular matrix components that are deposited within the tumor, the tumor microenvironment, and at metastatic site(s), and are recognized to play essential roles during metastasis development. Here, we review recent findings on the metastatic role of the collagen receptors Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2) in CRC and discuss the therapeutic value of targeting these receptor tyrosine kinases in this cancer.
结直肠癌(CRC)是全球肿瘤相关死亡的主要原因之一。虽然手术可以治愈早期CRC患者,但转移性疾病患者的5年生存率仅为10%。因此,这种癌症需要新的抗转移疗法。转移扩散定义了具有肿瘤起始能力的癌细胞从原发性肿瘤的播散及其在不同器官(主要是肝脏)的定植,以形成继发性肿瘤。尽管其潜在机制尚未完全了解,但肿瘤微环境的成分已引起了强烈关注。在已知的促转移因子中,胶原蛋白是沉积在肿瘤、肿瘤微环境和转移部位的细胞外基质成分,并且被认为在转移发展过程中起重要作用。在这里,我们综述了胶原蛋白受体盘状结构域受体1和2(DDR1和DDR2)在CRC中的转移作用的最新发现,并讨论了在这种癌症中靶向这些受体酪氨酸激酶的治疗价值。